AcedrA BioPharmaceuticals

What AcedrA BioPharmaceuticals does

AcedrA BioPharmaceuticals (legal entity: AcedrA Pharmaceutical Company LLC) is a privately held pharmaceutical services and specialty distribution company headquartered in Riyadh, Saudi Arabia, founded in 2017 to address unmet medical needs across the Middle East and North Africa. The company operates a hybrid platform that combines physical distribution of specialty pharmaceuticals, orphan drugs, and medical devices with a portfolio of professional services including licensing support, managed and early access programs, regulatory and medical affairs management, full agency commercialization, pharmacovigilance, and advisory/consultancy. It continuously monitors the clinical pipelines of over 1,000 global biotechnology and medical companies to identify therapeutics suitable for MENA market entry.

The business is organized into three units — Unmet Medical Needs, Unmet Commercial Needs, and Medical Technology — and operates from offices in Riyadh (headquarters and central logistics warehouse), Tunis (North Africa regional HQ), and Dubai (UAE office), serving customers in more than 8 MENA countries and shipping over 3 million units annually. Revenue is generated through multiple streams: licensing royalties, professional services fees for regulatory and managed-access work, managed services for full agency engagements, and distribution margin on sourced pharmaceuticals and medical devices, all priced via direct B2B negotiation with pharmaceutical and biotech partners and healthcare facilities. The company maintains a structured executive team (CEO Hosni STA, Chairman Bkheet ALDOSARI, CFO Amjad Qasem, CCO Layla WAHABI, GM Mesfer ALDOSARI), is opening an investor-facing capital channel, and is preparing to launch the AcedrA Institute, a digital knowledge platform for healthcare professionals.

Name

AcedrA BioPharmaceuticals

Legal name

AcedrA Pharmaceutical Company LLC

Website

https://acedrarx.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

51–100 employees

Short description

AcedrA BioPharmaceuticals is a Riyadh-based hybrid platform founded in 2017 that combines specialty pharmaceutical distribution with licensing, regulatory, early-access, and commercialization services for pharma and biotech companies seeking to enter the MENA region.

Ownership category

akta.pro rank

Product category

Pharmaceutical Services

NAICS

Professional, Scientific, and Technical Services (54), Other Scientific and Technical Consulting Services (54169)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Services-Management Services (8741)

akta.pro industry

PRIMARYHLAIACAO

Specialty Injectable & Infusion Therapies (Cross-therapeutic)

Healthcare & Life Sciences/Pharmaceuticals/Specialty Pharmaceuticals

SECONDARYHLAGAHAM

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

SECONDARYBPAHADAA

Corporate Strategy Advisory

Business & Public Services/Professional Services (Legal, Accounting, Consulting)/Strategy & Corporate Finance Advisory

Keywords

• Pharmaceutical licensing services
• Managed access programs
• Regulatory affairs consulting
• Pharma distribution services
• Biotech commercialization

Headquarters

HQ city

Riyadh

HQ country

Saudi Arabia

HQ region

Middle East

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Supply Chain, Technology or R&D

Revenue model

1. Licensing Services: AcedrA provides licensing services to pharmaceutical companies seeking to enter or expand in the MENA market, facilitating the authorization of their products for distribution in the region.
2. Managed & Early Access Programs: The company generates revenue through early access and managed access programs that enable patients in the MENA region to access treatments not yet commercially available, charging for program management and product sourcing services.
3. Regulatory & Medical Affairs Management: AcedrA provides regulatory and medical affairs services to pharmaceutical companies, helping navigate regional regulatory requirements for product approval and market entry.
4. Distribution & Supply Chain: The company distributes specialty pharmaceuticals, medical devices, and equipment to the MENA region, earning margin on products sourced from manufacturers and authorized distributors.
5. Full Agency Management: AcedrA provides comprehensive agency management services for pharmaceutical companies, handling commercialization activities in the MENA region on behalf of product owners.
6. Advisory & Consultancy: The company offers advisory and consultancy services to pharmaceutical and biotechnology companies seeking strategic guidance on market entry and operations in the MENA region.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

AcedrA BioPharmaceuticals is a regional pharmaceutical services partner that helps pharmaceutical and biotechnology companies commercialize and provide access to their products across the MENA region. Its service portfolio spans in-licensing, early and managed access programs, regulatory and medical affairs, distribution and supply chain management, full agency management (commercializing products on behalf of partners), and strategic advisory services addressing unmet medical and commercial needs.

Product overview

AcedrA BioPharmaceuticals is a regional pharmaceutical services company serving the MENA region since 2017. The company offers a comprehensive suite of services organized around three core business units: the Unmet Medical Needs unit, the Unmet Commercial Needs unit, and the Medical Technology unit. The core service portfolio includes Licensing, Managed & Early Access Programs, Regulatory & Medical Affairs Management, Distribution & Supply Chain Management, Full Agency Management, and Advisory & Consultancy. The Access Sourcing unit handles distribution of specialty pharmaceuticals and medical devices, while Access Innovation serves as a hybrid platform for clinical and commercial success. AcedrA Institute is an upcoming digital knowledge platform for healthcare professionals. The company also provides pharmacovigilance services for drug safety monitoring. All services are delivered with a focus on making innovation affordable for patients and scientific communities in the Middle East and North Africa.

Differentiator

Problem solved

Functional benefit

Brands

• AcedrA Institute: A comprehensive digital platform providing healthcare professionals access to up-to-date information about therapeutics and medical technologies across various specialties.

Products and services

• Licensing Services In-licensing of pharmaceutical and biotech products for commercialization across MENA markets on behalf of manufacturer partners. Intended for pharma and biotech principals seeking regional market entry without a local affiliate.
• Early & Managed Access Programs Design and operation of early access and managed access programs that enable patients to receive pharmaceutical products before full commercial availability. Intended for pharma and biotech principals and the healthcare providers and patients they serve across MENA.
• Regulatory & Medical Affairs Regulatory affairs and medical affairs support covering market authorization, lifecycle maintenance, and medical/scientific engagement across MENA health authorities. Intended for pharma and biotech manufacturers seeking compliant regional filings and medical-scientific support.
• Distribution & Supply Chain Pharmaceutical distribution and supply chain management across Saudi Arabia, UAE, Tunisia, and Egypt. Intended for pharma and biotech principals that need regional logistics and last-mile delivery without a local affiliate.
• Full Agency Management End-to-end commercialization of pharmaceutical products on behalf of partners across MENA, combining licensing, regulatory, distribution, and commercial execution under a single mandate. Intended for pharma and biotech principals that want an asset-light regional presence.
• Advisory & Consultancy Strategic advisory and consultancy supporting pharmaceutical and biotech partners on MENA market entry, access strategy, and unmet medical/commercial need identification. Intended for pharma and biotech decision-makers evaluating regional expansion.

Quantifiable outcome

• Supplying customers in over 8 countries
• +2 more outcomes

Segments4 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Regional players

• EIPICO (Egyptian International Pharmaceutical Industries Company): One of the largest Egyptian pharmaceutical manufacturers with regional MENA reach. Comparable to AcedrA as a regional specialty pharma player, though primarily a manufacturer and Egypt-anchored.
• Pharma International Co: Jordanian pharmaceutical manufacturer with established distribution across the Levant and selected Gulf markets. Comparable to AcedrA's regional specialty pharma distribution model, although its core manufacturing footprint is in Jordan.

Direct peers

• Hikma Pharmaceuticals: Jordan-headquartered specialty and generics pharma company with substantial MENA manufacturing and distribution operations. Comparable to AcedrA as a regional specialty pharma player combining proprietary products with regional distribution across KSA, UAE, and North Africa.
• Julphar (Gulf Pharmaceutical Industries): UAE-based pharmaceutical manufacturer and regional distributor serving the MENA market with branded generics and specialty products. Comparable to AcedrA's UAE hub and MENA distribution focus, although Julphar is also a manufacturer.
• Avalon Pharma: Privately held Saudi pharmaceutical company focused on specialty and niche therapy areas with MENA distribution. Comparable to AcedrA's specialty pharma focus and KSA-centric operational footprint.
• Tabuk Pharmaceuticals: Saudi pharmaceutical manufacturer and distributor with strong domestic presence and selected MENA exports. Comparable to AcedrA as a Saudi-anchored specialty pharma company serving regional healthcare providers.
• Mundipharma: Independent specialty pharma company with established MENA commercial operations focused on pain, respiratory, and specialty therapy areas. Comparable to AcedrA's specialty pharma distribution and access focus, with similar emphasis on bringing originator products into regional markets.

Others

• IQVIA MENA: Global life sciences services and data company with MENA operations spanning commercial outsourcing, regulatory support, and market access consulting. Comparable to AcedrA's regulatory, advisory, and market access services as a much larger, globally backed incumbent.

Broad incumbents

• SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation): One of the largest publicly listed Saudi pharmaceutical companies, with broader branded generics and OTC portfolios than AcedrA. Comparable as a KSA-headquartered pharma operator, but operates at significantly larger scale and as a manufacturer rather than a services-led distributor.

Emerging players

• Clinart (MENA CRO): Regional clinical research organization serving pharma and biotech sponsors across MENA. Comparable to AcedrA on the services side (regulatory affairs, clinical support) rather than distribution, and overlaps in providing MENA market entry support to biotech clients.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/AcedrABioPharma
• Facebookfacebook.com/884787868389932
• LinkedInlinkedin.com/company/acedra-biopharmaceuticals/mycompany/?viewAsMember=true

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AcedrA BioPharmaceuticals